Abstract:
Compounds of formula (I), where: R1, R2, R3, R4 are as defined in the description, the enantiomers, diastereomers, tautomers and addition salts thereof with a pharmaceutically-acceptable acid or base. Said compounds have kinase modulating properties and are useful in the treatment of cancer, diabetes, obesity etc.
Abstract:
Compounds of formula (I), where: R1, R2, R3 and R4 are as defined in the description, the enantiomers, diastereomers, tautomers and addition salts thereof with a pharmaceutically-acceptable acid or base. The compounds have kinase modulating properties and are useful in the treatment of cancer, diabetes and obesity.
Abstract:
Imidazopyridine derivatives (I) are new. Imidazopyridine derivatives of formula (I), their enantiomers, diastereoisomers, and their salts with acids and bases are new. R1 = H, halogen, alkyl, polyhaloalkyl, CN, NO2, hydroxycarbonyl, alkoxycarbonyl, aminocarbonyl, or dialkylaminocarbonyl; R2 = H, alkyl, aryl (optionally substituted), heteroaryl (optionally substituted) or a group of formula R20-C(X)-; R20 = alkyl, alkoxy, amino, alkylamino, dialkylamino, aryl (optionally substituted), or heteroaryl (optionally substituted); X = O, S, or NR21; R21, R3 = H or alkyl; n = 1-6; and N = pyrido ring with the N atom in the 1, 2, 3, or 4 positions. Alkyl and alkoxy groups have 1-6 C atoms, aryl is phenyl or naphthyl, polyhaloalkyl groups having 1-3 C atoms and 1-7 halogen atoms, heteroaryl groups may be mono or bicyclic of 5 - 11 ring atoms, at least one ring being aromatic, and having 2 or 3 heteroatoms (O, N, S) and may be substituted by 1-3 alkyl groups. Optional substituents on aryl groups may be 1 or 2 substituents selected from halogens, alkyl, alkoxy, polyhaloalkyl, hydroxy, CN, NO2, amino, alkylamino, dialkylamino, carboxyl, amido, and -COO-alkyl groups, and heteroaryl groups having a non-aromatic ring may be further substituted on this non-aromatic ring by oxo.
Abstract:
Pyridopyrimidone derivatives (I), their enantiomers, diastereoisomers, tautomers, and their salts with acids and bases are new. Pyridopyrimidone derivatives of formula (I), their enantiomers, diastereoisomers, tautomers, and their salts with acids and bases are new. R1, R2 = H or alkyl; R3 = halogen, alkoxy, aryl (optionally substituted by 1-3 R33), or NR'1R'2; R'1, R'2 = H, alkyl, or R'1-N-R'2 is a heterocycle; R4 = H or NR''1R''2; R''1, R''2 = H or alkyl; R1+R2, R'1+R'2, R''1+R''2 = mono or bicyclic of 5 - 11 C heterocycle optionally containing a further 1 or 2 heteroatoms (O, N, S), optionally substituted by 1-3 alkyl groups; R33 = halogens, alkyl, alkoxy, polyhaloalkyl (containing 1 - 3 C atoms and 1 - 7 halogen atoms) and hydroxy; provided that: (1) alkyl and alkoxy groups have 1 - 8 C atoms, aryl is phenyl or naphthyl; and An Independent claim is also included for the preparation of (I).
Abstract:
2,3-Dihydro-4(1H)-pyridinone derivatives (I), their enantiomers, diastereoisomers, and acid addition salts are new. 2,3-Dihydro-4(1H)-pyridinone derivatives (I), their enantiomers, diastereoisomers, and acid addition salts are new. R1 = H, 1-6C alkyl, acyl, alkoxycarbonyl, aralkyl aralkoxycarbonyl, or trifluoroacetyl; R2 = 1-6C alkyl; X = O or NOR3; R3 = H, 1-6C alkyl (optionally substituted by OH, amino, alkylamino, dialkylamino and alkoxy); Ar = aryl or heteroaryl where aryl groups may be phenyl, biphenylyl, naphthyl, or tetrahydronaphthyl, all of which are optionally substituted by halogens, alkyl, OH, alkoxy, trihalomethyl, nitro, amino, alkylamino and dialkylamino groups, and heteroaryl groups may be mono or bicyclic and may be substituted by halogens, alkyl, OH, alkoxy, trihalomethyl, nitro, amino, alkylamino and dialkylamino groups.
Abstract:
Imidazoline derivatives (I), their enantiomers, diastereoisomers, tautomers, and salts with acids and bases, are new. Imidazoline derivatives of formula (I), their enantiomers, diastereoisomers, tautomers, and salts with acids and bases, are new: R1 = heteroaryl optionally substituted by T1; R2 = cycloalkyl optionally substituted by T1; T1 = halogen, alkyl, alkoxy, OH, CN, NO2, (di)(alkyl)amino, COOH, COO-alkyl or CONH2-C(O)Rd; Rd = OH, alkoxy or amino; R4 , R5 = H, halogen, (polyhalo)alkyl, R10-C(X)-R11-, R10-Y-C(X)-R11-, R11-Y-R11-, or R10-S-(O)n-R11-; R11 = a bond, alkylene, alkenylene or alkynylene; X = O, S, or NR12; R3, R10, R12 = H or alkyl; Y = O, S or (alkyl)amino; and n = 1 or 2. Alkyl, alkoxy and alkylene have 1-6C, alkenylene have 2-6C and 1-3 double bonds, alkynylene have 2-6C and 1-3 triple bonds, polyhaloalkyl have 1-3C and 1-7 halogens, heteroaryl has 5 - 11 members and is mono or bicyclic with at least one aromatic ring and with 1-3 heteroatoms selected from O, N and S and may be substituted by an oxo group on a non-aromatic part of the structure, cycloalkyl has 3-10C, is mono or bicyclic and may have 1 or 2 unsaturations. An Independent claim is also included for the preparation of (I).
Abstract:
Imidazopyridine derivatives (I) are new. Imidazopyridine derivatives of formula (I), their enantiomers, diastereoisomers, and their salts with acids and bases are new. R1 = H, halogen, alkyl, polyhaloalkyl, CN, NO2, hydroxycarbonyl, alkoxycarbonyl, aminocarbonyl, or dialkylaminocarbonyl; R2 = H, alkyl, aryl (optionally substituted), heteroaryl (optionally substituted) or a group of formula R20-C(X)-; R20 = alkyl, alkoxy, amino, alkylamino, dialkylamino, aryl (optionally substituted), or heteroaryl (optionally substituted); X = O, S, or NR21; R21, R3 = H or alkyl; n = 1-6; and N = pyrido ring with the N atom in the 1, 2, 3, or 4 positions. Alkyl and alkoxy groups have 1-6 C atoms, aryl is phenyl or naphthyl, polyhaloalkyl groups having 1-3 C atoms and 1-7 halogen atoms, heteroaryl groups may be mono or bicyclic of 5 - 11 ring atoms, at least one ring being aromatic, and having 2 or 3 heteroatoms (O, N, S) and may be substituted by 1-3 alkyl groups. Optional substituents on aryl groups may be 1 or 2 substituents selected from halogens, alkyl, alkoxy, polyhaloalkyl, hydroxy, CN, NO2, amino, alkylamino, dialkylamino, carboxyl, amido, and -COO-alkyl groups, and heteroaryl groups having a non-aromatic ring may be further substituted on this non-aromatic ring by oxo.
Abstract:
Imidazoline derivatives (I), their enantiomers, diastereoisomers, tautomers, and salts with acids and bases, are new. Imidazoline derivatives of formula (I), their enantiomers, diastereoisomers, tautomers, and salts with acids and bases, are new: R1 = heteroaryl optionally substituted by T1; R2 = cycloalkyl optionally substituted by T1; T1 = halogen, alkyl, alkoxy, OH, CN, NO2, (di)(alkyl)amino, COOH, COO-alkyl or CONH2-C(O)Rd; Rd = OH, alkoxy or amino; R4 , R5 = H, halogen, (polyhalo)alkyl, R10-C(X)-R11-, R10-Y-C(X)-R11-, R11-Y-R11-, or R10-S-(O)n-R11-; R11 = a bond, alkylene, alkenylene or alkynylene; X = O, S, or NR12; R3, R10, R12 = H or alkyl; Y = O, S or (alkyl)amino; and n = 1 or 2. Alkyl, alkoxy and alkylene have 1-6C, alkenylene have 2-6C and 1-3 double bonds, alkynylene have 2-6C and 1-3 triple bonds, polyhaloalkyl have 1-3C and 1-7 halogens, heteroaryl has 5 - 11 members and is mono or bicyclic with at least one aromatic ring and with 1-3 heteroatoms selected from O, N and S and may be substituted by an oxo group on a non-aromatic part of the structure, cycloalkyl has 3-10C, is mono or bicyclic and may have 1 or 2 unsaturations. An Independent claim is also included for the preparation of (I).
Abstract:
Imidazopyridine derivatives (I) are new. Imidazopyridine derivatives of formula (I), their enantiomers, diastereoisomers, and their salts with acids and bases are new. R1 = H, halogen, alkyl, polyhaloalkyl, CN, NO2, hydroxycarbonyl, alkoxycarbonyl, aminocarbonyl, or dialkylaminocarbonyl; R2 = H, alkyl, aryl (optionally substituted), heteroaryl (optionally substituted) or a group of formula R20-C(X)-; R20 = alkyl, alkoxy, amino, alkylamino, dialkylamino, aryl (optionally substituted), or heteroaryl (optionally substituted); X = O, S, or NR21; R21, R3 = H or alkyl; n = 1-6; and N = pyrido ring with the N atom in the 1, 2, 3, or 4 positions. Alkyl and alkoxy groups have 1-6 C atoms, aryl is phenyl or naphthyl, polyhaloalkyl groups having 1-3 C atoms and 1-7 halogen atoms, heteroaryl groups may be mono or bicyclic of 5 - 11 ring atoms, at least one ring being aromatic, and having 2 or 3 heteroatoms (O, N, S) and may be substituted by 1-3 alkyl groups. Optional substituents on aryl groups may be 1 or 2 substituents selected from halogens, alkyl, alkoxy, polyhaloalkyl, hydroxy, CN, NO2, amino, alkylamino, dialkylamino, carboxyl, amido, and -COO-alkyl groups, and heteroaryl groups having a non-aromatic ring may be further substituted on this non-aromatic ring by oxo.